Cargando…

Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children

BACKGROUND: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of the vaccine at peak response, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubillos, Itziar, Ayestaran, Aintzane, Nhabomba, Augusto J, Dosoo, David, Vidal, Marta, Jiménez, Alfons, Jairoce, Chenjerai, Sanz, Hèctor, Aguilar, Ruth, Williams, Nana Aba, Díez-Padrisa, Núria, Mpina, Maximilian, Sorgho, Hermann, Agnandji, Selidji Todagbe, Kariuki, Simon, Mordmüller, Benjamin, Daubenberger, Claudia, Asante, Kwaku Poku, Owusu-Agyei, Seth, Sacarlal, Jahit, Aide, Pedro, Aponte, John J, Dutta, Sheetij, Gyan, Ben, Campo, Joseph J, Valim, Clarissa, Moncunill, Gemma, Dobaño, Carlota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208122/
https://www.ncbi.nlm.nih.gov/pubmed/30376866
http://dx.doi.org/10.1186/s12916-018-1186-4
_version_ 1783366656780664832
author Ubillos, Itziar
Ayestaran, Aintzane
Nhabomba, Augusto J
Dosoo, David
Vidal, Marta
Jiménez, Alfons
Jairoce, Chenjerai
Sanz, Hèctor
Aguilar, Ruth
Williams, Nana Aba
Díez-Padrisa, Núria
Mpina, Maximilian
Sorgho, Hermann
Agnandji, Selidji Todagbe
Kariuki, Simon
Mordmüller, Benjamin
Daubenberger, Claudia
Asante, Kwaku Poku
Owusu-Agyei, Seth
Sacarlal, Jahit
Aide, Pedro
Aponte, John J
Dutta, Sheetij
Gyan, Ben
Campo, Joseph J
Valim, Clarissa
Moncunill, Gemma
Dobaño, Carlota
author_facet Ubillos, Itziar
Ayestaran, Aintzane
Nhabomba, Augusto J
Dosoo, David
Vidal, Marta
Jiménez, Alfons
Jairoce, Chenjerai
Sanz, Hèctor
Aguilar, Ruth
Williams, Nana Aba
Díez-Padrisa, Núria
Mpina, Maximilian
Sorgho, Hermann
Agnandji, Selidji Todagbe
Kariuki, Simon
Mordmüller, Benjamin
Daubenberger, Claudia
Asante, Kwaku Poku
Owusu-Agyei, Seth
Sacarlal, Jahit
Aide, Pedro
Aponte, John J
Dutta, Sheetij
Gyan, Ben
Campo, Joseph J
Valim, Clarissa
Moncunill, Gemma
Dobaño, Carlota
author_sort Ubillos, Itziar
collection PubMed
description BACKGROUND: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of the vaccine at peak response, the factors affecting it, and the antibodies associated with protection against clinical malaria in young African children participating in the multicenter phase 3 trial for licensure. METHODS: We measured total IgM, IgG, and IgG(1–4) subclass antibodies to three constructs of the Plasmodium falciparum circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg) that are part of the RTS,S vaccine, by quantitative suspension array technology. Plasma and serum samples were analyzed in 195 infants and children from two sites in Ghana (Kintampo) and Mozambique (Manhiça) with different transmission intensities using a case-control study design. We applied regression models and machine learning techniques to analyze immunogenicity, correlates of protection, and factors affecting them. RESULTS: RTS,S/AS01E induced IgM and IgG, predominantly IgG1 and IgG3, but also IgG2 and IgG4, subclass responses. Age, site, previous malaria episodes, and baseline characteristics including antibodies to CSP and other antigens reflecting malaria exposure and maternal IgGs, nutritional status, and hemoglobin concentration, significantly affected vaccine immunogenicity. We identified distinct signatures of malaria protection and risk in RTS,S/AS01E but not in comparator vaccinees. IgG2 and IgG4 responses to RTS,S antigens post-vaccination, and anti-CSP and anti-P. falciparum antibody levels pre-vaccination, were associated with malaria risk over 1-year follow-up. In contrast, antibody responses to HBsAg (all isotypes, subclasses, and timepoints) and post-vaccination IgG1 and IgG3 to CSP C-terminus and NANP were associated with protection. Age and site affected the relative contribution of responses in the correlates identified. CONCLUSIONS: Cytophilic IgG responses to the C-terminal and NANP repeat regions of CSP and anti-HBsAg antibodies induced by RTS,S/AS01E vaccination were associated with malaria protection. In contrast, higher malaria exposure at baseline and non-cytophilic IgG responses to CSP were associated with disease risk. Data provide new correlates of vaccine success and failure in African children and reveal key insights into the mode of action that can guide development of more efficacious next-generation vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-018-1186-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6208122
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62081222018-11-16 Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children Ubillos, Itziar Ayestaran, Aintzane Nhabomba, Augusto J Dosoo, David Vidal, Marta Jiménez, Alfons Jairoce, Chenjerai Sanz, Hèctor Aguilar, Ruth Williams, Nana Aba Díez-Padrisa, Núria Mpina, Maximilian Sorgho, Hermann Agnandji, Selidji Todagbe Kariuki, Simon Mordmüller, Benjamin Daubenberger, Claudia Asante, Kwaku Poku Owusu-Agyei, Seth Sacarlal, Jahit Aide, Pedro Aponte, John J Dutta, Sheetij Gyan, Ben Campo, Joseph J Valim, Clarissa Moncunill, Gemma Dobaño, Carlota BMC Med Research Article BACKGROUND: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of the vaccine at peak response, the factors affecting it, and the antibodies associated with protection against clinical malaria in young African children participating in the multicenter phase 3 trial for licensure. METHODS: We measured total IgM, IgG, and IgG(1–4) subclass antibodies to three constructs of the Plasmodium falciparum circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg) that are part of the RTS,S vaccine, by quantitative suspension array technology. Plasma and serum samples were analyzed in 195 infants and children from two sites in Ghana (Kintampo) and Mozambique (Manhiça) with different transmission intensities using a case-control study design. We applied regression models and machine learning techniques to analyze immunogenicity, correlates of protection, and factors affecting them. RESULTS: RTS,S/AS01E induced IgM and IgG, predominantly IgG1 and IgG3, but also IgG2 and IgG4, subclass responses. Age, site, previous malaria episodes, and baseline characteristics including antibodies to CSP and other antigens reflecting malaria exposure and maternal IgGs, nutritional status, and hemoglobin concentration, significantly affected vaccine immunogenicity. We identified distinct signatures of malaria protection and risk in RTS,S/AS01E but not in comparator vaccinees. IgG2 and IgG4 responses to RTS,S antigens post-vaccination, and anti-CSP and anti-P. falciparum antibody levels pre-vaccination, were associated with malaria risk over 1-year follow-up. In contrast, antibody responses to HBsAg (all isotypes, subclasses, and timepoints) and post-vaccination IgG1 and IgG3 to CSP C-terminus and NANP were associated with protection. Age and site affected the relative contribution of responses in the correlates identified. CONCLUSIONS: Cytophilic IgG responses to the C-terminal and NANP repeat regions of CSP and anti-HBsAg antibodies induced by RTS,S/AS01E vaccination were associated with malaria protection. In contrast, higher malaria exposure at baseline and non-cytophilic IgG responses to CSP were associated with disease risk. Data provide new correlates of vaccine success and failure in African children and reveal key insights into the mode of action that can guide development of more efficacious next-generation vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-018-1186-4) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-31 /pmc/articles/PMC6208122/ /pubmed/30376866 http://dx.doi.org/10.1186/s12916-018-1186-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ubillos, Itziar
Ayestaran, Aintzane
Nhabomba, Augusto J
Dosoo, David
Vidal, Marta
Jiménez, Alfons
Jairoce, Chenjerai
Sanz, Hèctor
Aguilar, Ruth
Williams, Nana Aba
Díez-Padrisa, Núria
Mpina, Maximilian
Sorgho, Hermann
Agnandji, Selidji Todagbe
Kariuki, Simon
Mordmüller, Benjamin
Daubenberger, Claudia
Asante, Kwaku Poku
Owusu-Agyei, Seth
Sacarlal, Jahit
Aide, Pedro
Aponte, John J
Dutta, Sheetij
Gyan, Ben
Campo, Joseph J
Valim, Clarissa
Moncunill, Gemma
Dobaño, Carlota
Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
title Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
title_full Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
title_fullStr Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
title_full_unstemmed Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
title_short Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
title_sort baseline exposure, antibody subclass, and hepatitis b response differentially affect malaria protective immunity following rts,s/as01e vaccination in african children
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208122/
https://www.ncbi.nlm.nih.gov/pubmed/30376866
http://dx.doi.org/10.1186/s12916-018-1186-4
work_keys_str_mv AT ubillositziar baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT ayestaranaintzane baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT nhabombaaugustoj baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT dosoodavid baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT vidalmarta baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT jimenezalfons baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT jairocechenjerai baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT sanzhector baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT aguilarruth baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT williamsnanaaba baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT diezpadrisanuria baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT mpinamaximilian baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT sorghohermann baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT agnandjiselidjitodagbe baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT kariukisimon baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT mordmullerbenjamin baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT daubenbergerclaudia baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT asantekwakupoku baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT owusuagyeiseth baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT sacarlaljahit baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT aidepedro baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT apontejohnj baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT duttasheetij baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT gyanben baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT campojosephj baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT valimclarissa baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT moncunillgemma baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren
AT dobanocarlota baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren